Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share

Rhea-AI Summary

Simulations Plus (Nasdaq: SLP) has declared a quarterly cash dividend of $0.06 per share, set for distribution on November 2, 2020. Shareholders of record by October 26, 2020 will receive this dividend, continuing the board's commitment to regular quarterly dividends. The board will evaluate future dividends based on the company's earnings, financial condition, and capital requirements. Simulations Plus specializes in modeling and simulation solutions for the pharmaceutical and biotechnology sectors.

Positive

• Quarterly cash dividend of $0.06 will enhance shareholder value.
• Company's commitment to consistent dividend payments reflects strong financial health.
• Simulations Plus is positioned as a leader in simulation solutions for critical sectors.

Negative

• None.

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that its board of directors has declared another quarterly cash dividend of $0.06 per share of the Company’s common stock. The cash dividend will be distributed on Monday, November 2, 2020, to shareholders of record as of Monday, October 26, 2020.

Walt Woltosz, chairman of the board of directors, said, “This dividend declaration is a continuation of the Board’s plan to distribute a cash dividend of $0.06 per share per quarter. The declaration of any future dividends will be determined by the board of directors each quarter and will depend on earnings, financial condition, capital requirements, and other factors.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com.

Follow us on Twitter | LinkedIn